399 related articles for article (PubMed ID: 29130362)
1. Is serum bilirubin associated with the severity of Guillain-Barré syndrome?
Li X; Li W; Shi X; Mo L; Luo Y; Qin L; Yang Z; Mo W
Int J Neurosci; 2018 Jul; 128(7):595-599. PubMed ID: 29130362
[TBL] [Abstract][Full Text] [Related]
2. Serum Folate Correlates with Severity of Guillain-Barré Syndrome and Predicts Disease Progression.
Gao Y; Zhang HL; Xin M; Wang D; Zheng N; Wang S; Xu J; Wang Y; Zhu J; Feng J
Biomed Res Int; 2018; 2018():5703279. PubMed ID: 30013984
[TBL] [Abstract][Full Text] [Related]
3. Can we assess severity of Guillain-Barré syndrome using absolute monocyte count?
Li X; Li W; Luo Y; Qin L; Su Q; Mo W
Int J Lab Hematol; 2018 Aug; 40(4):488-492. PubMed ID: 29718547
[TBL] [Abstract][Full Text] [Related]
4. Dynamic thiol-disulphide homeostasis in patients with Guillain-Barre Syndrome.
Gümüşyayla Ş; Vural G; Yurtoğulları Çevik Ş; Akdeniz G; Neselioğlu S; Deniz O; Erel Ö
Neurol Res; 2019 May; 41(5):413-418. PubMed ID: 30730791
[TBL] [Abstract][Full Text] [Related]
5. Ganglionic acetylcholine receptor autoantibodies in patients with Guillain-Barré syndrome.
Nakane S; Higuchi O; Hamada Y; Maeda Y; Mukaino A; Sakai W; Kusunoki S; Matsuo H
J Neuroimmunol; 2016 Jun; 295-296():54-9. PubMed ID: 27235349
[TBL] [Abstract][Full Text] [Related]
6. Thyroid hormone level is associated with the frequency and severity of Guillain-Barré syndrome.
Huang Y; Ying Z; Chen Z; Xiang W; Su Z; Quan W; Weng Y; Zhang X
Int J Neurosci; 2017 Oct; 127(10):893-899. PubMed ID: 28042737
[TBL] [Abstract][Full Text] [Related]
7. Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barré syndrome.
Zhang LJ; Guo HY; Zhang DQ; Wang R; Li T; Li LM; Suo DM; Yang L
Clin Chim Acta; 2017 May; 468():5-9. PubMed ID: 28167198
[TBL] [Abstract][Full Text] [Related]
8. Fasting Glucose Levels Correlate with Disease Severity of Guillain-Barré Syndrome.
Wang Y; Li G; Yang S; Gu X; Li X; Liu M; Wu X; Guan Y; Press R; Zhu J; Zhang HL
PLoS One; 2015; 10(12):e0145075. PubMed ID: 26684748
[TBL] [Abstract][Full Text] [Related]
9. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
[TBL] [Abstract][Full Text] [Related]
10. Disturbance of Plasma Lipid Metabolic Profile in Guillain-Barre Syndrome.
Tang HY; Chiu DT; Lin JF; Huang CY; Chang KH; Lyu RK; Ro LS; Kuo HC; Cheng ML; Chen CM
Sci Rep; 2017 Aug; 7(1):8140. PubMed ID: 28811529
[TBL] [Abstract][Full Text] [Related]
11. No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barré Syndrome in a Brazilian population.
Dourado ME; Ferreira LC; Freire-Neto FP; Jeronimo SM
J Neuroimmunol; 2016 Sep; 298():160-4. PubMed ID: 27609290
[TBL] [Abstract][Full Text] [Related]
12. Remnant Cholesterol and Dyslipidemia Are Risk Factors for Guillain-Barré Syndrome and Severe Guillain-Barré Syndrome by Promoting Monocyte Activation.
Ding Y; Wang L; Sun J; Shi Y; Li G; Luan X; Zheng G; Zhang G
Front Immunol; 2022; 13():946825. PubMed ID: 35911688
[TBL] [Abstract][Full Text] [Related]
13. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study.
Yamagishi Y; Suzuki H; Sonoo M; Kuwabara S; Yokota T; Nomura K; Chiba A; Kaji R; Kanda T; Kaida K; Ikeda SI; Mutoh T; Yamasaki R; Takashima H; Matsui M; Nishiyama K; Sobue G; Kusunoki S
J Peripher Nerv Syst; 2017 Dec; 22(4):433-439. PubMed ID: 28833828
[TBL] [Abstract][Full Text] [Related]
14. The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome.
Li C; Luo T; Cheng Y; Liu S; Qiao L; Wu X; Liu K
Neurol Sci; 2020 Feb; 41(2):295-303. PubMed ID: 31494821
[TBL] [Abstract][Full Text] [Related]
15. Zika virus disease-associated Guillain-Barré syndrome-Barranquilla, Colombia 2015-2016.
Salinas JL; Walteros DM; Styczynski A; Garzón F; Quijada H; Bravo E; Chaparro P; Madero J; Acosta-Reyes J; Ledermann J; Arteta Z; Borland E; Burns P; Gonzalez M; Powers AM; Mercado M; Solano A; Sejvar JJ; Ospina ML
J Neurol Sci; 2017 Oct; 381():272-277. PubMed ID: 28991697
[TBL] [Abstract][Full Text] [Related]
16. FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barré syndrome.
Islam Z; Jahan I; Ahammad RU; Shahnaij M; Nahar S; Mohammad QD
PLoS One; 2018; 13(2):e0192703. PubMed ID: 29432441
[TBL] [Abstract][Full Text] [Related]
17. Clinically diagnosed Guillain-Barre syndrome in Ile-Ife, Nigeria.
Sunmonu TA; Komolafe MA; Adewuya A; Olugbodi AA
West Afr J Med; 2008 Jul; 27(3):167-70. PubMed ID: 19256323
[TBL] [Abstract][Full Text] [Related]
18. Diabetes mellitus may affect short-term outcome of Guillain-Barré syndrome.
Peric S; Bozovic I; Bjelica B; Berisavac I; Stojiljkovic O; Basta I; Beslac-Bumbasirevic L; Rakocevic-Stojanovic V; Lavrnic D; Stevic Z
J Peripher Nerv Syst; 2017 Jun; 22(2):127-130. PubMed ID: 28177572
[TBL] [Abstract][Full Text] [Related]
19. Memory B cells in Guillain-Barré syndrome.
Wang Q; Xing C; Hao Y; Shi Q; Qi Z; Lv Z; Song Y; Xu P; Feng X; Zhang L; Zhang Y; Wang Y; Yuki N
J Neuroimmunol; 2017 Apr; 305():1-4. PubMed ID: 28284328
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Cerebrospinal Fluid Total Protein and Serum Neutrophil-to-Lymphocyte Ratio with Clinical Outcomes of Guillain-Barre Syndrome Variants.
Bano S; Nawaz A; Nasim A; Numan A; Zahid M
J Coll Physicians Surg Pak; 2024 Feb; 34(2):187-192. PubMed ID: 38342870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
